YMAB - Y-mAbs Therapeutics Inc Company Long-Term Liabilities

Y-mAbs Therapeutics (YMAB) is implementing robotic systems for antibody cultivation, eliminating manual labor during drug filling. The market capitalization trend reflects this process, with the current figure standing at 0.00. Despite fierce patent battles in pediatric oncology, the business relies on a steady cash flow from sales of its approved drug, which allows the company to fully fund its own R&D.

For Y-mAbs Therapeutics (YMAB), which relies on external CMO antibody manufacturers, this indicator captures the volume of borrowed funds with a maturity of more than one year. The metric measures long-term credit load, reflecting the balance between capital raising and the growth of interest obligations. An analysis of the company's long-term debt allows for the tracking of financial stability during the execution of exclusive contracts. A stable level of borrowing confirms investment confidence in the scaling of the biopharmaceutical business.